Neuraminidase mutations conferring resistance to laninamivir lead to faster drug binding and dissociation

Antiviral Research

Volumn 114, Issue , 2015, Pages 62-66

  McKimm Breschkin, Jennifer L ^a   Barrett, Susan ^a  

^a CSIRO   (Australia)

Author keywords

Enzyme kinetics; Influenza; Laninamivir; Resistance

Indexed keywords

LANINAMIVIR; SIALIDASE; ANTIVIRUS AGENT; NA PROTEIN, INFLUENZA A VIRUS; NA PROTEIN, INFLUENZA B VIRUS; OSELTAMIVIR; VIRUS PROTEIN; ZANAMIVIR;

ANIMAL CELL; ANTIVIRAL RESISTANCE; ARTICLE; CLADISTICS; CROSS RESISTANCE; DISSOCIATION; DRUG EFFICACY; DRUG PROTEIN BINDING; ENZYME KINETICS; IC50; INFLUENZA VIRUS A H5N1; MDCK CELL LINE; NONHUMAN; VIRUS MUTANT; ANALOGS AND DERIVATIVES; ANIMAL; DOG; DRUG EFFECTS; ENZYMOLOGY; GENETICS; INFLUENZA VIRUS A; INFLUENZA VIRUS B; METABOLISM; MUTATION;

ANIMALS; ANTIVIRAL AGENTS; DOGS; DRUG RESISTANCE, VIRAL; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA B VIRUS; INHIBITORY CONCENTRATION 50; MADIN DARBY CANINE KIDNEY CELLS; MUTATION; NEURAMINIDASE; OSELTAMIVIR; VIRAL PROTEINS; ZANAMIVIR;

EID: 84919635486     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.12.004     Document Type: Article

References (24)

1. S. Bantia, R. Upshaw, and Y.S. Babu Characterization of the binding affinities of peramivir and oseltamivir carboxylate to the neuraminidase enzyme Antivir. Res. 91 2011 289 291
2. S. Barrett, and J.L. McKimm-Breschkin Solid phase assay for comparing reactivation rates of neuraminidases of influenza wild type and resistant mutants after inhibitor removal Antivir. Res. 108C 2014 30 35
3. S. Barrett, P.G. Mohr, P.M. Schmidt, and J.L. McKimm-Breschkin Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza viruses PLoS One 6 2011 e23627
4. E.Z. Baum, P.C. Wagaman, L. Ly, I. Turchi, J. Le, D. Bucher, and K. Bush A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding Antivir. Res. 59 2003 13 22
5. T.J. Blick, T. Tiong, A. Sahasrabudhe, J.N. Varghese, P.M. Colman, G.J. Hart, R.C. Bethell, and J.L. McKimm-Breschkin Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en Virology 214 1995 475 484
6. S. Fujisaki, E. Takashita, M. Yokoyama, T. Taniwaki, H. Xu, N. Kishida, H. Sato, M. Tashiro, M. Imai, and T. Odagiri A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs Biochem. Biophys. Res. Commun. 429 2012 51 56
7. G.J. Hart, and R.C. Bethell 2,3-Didehydro-2,4-dideoxy-4-guanidino-N-acetyl-d-neuraminic acid (4-guanidino-Neu5Ac2en) is a slow-binding inhibitor of sialidase from both influenza A virus and influenza B virus Biochem. Mol. Biol. Int. 36 1995 695 703
8. A.C. Hurt, P. Iannello, K. Jachno, N. Komadina, A.W. Hampson, I.G. Barr, and J.L. McKimm-Breschkin Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient Antimicrob. Agents Chemother. 50 2006 1872 1874
9. ISIRV Antiviral Group, 2014. NAI susceptibility reference panel. < http://www.isirv.org/site/index.php/reference-panel > (accessed March 2014).
10. M. Kakuta, S. Kubo, M. Tanaka, S. Tobiume, T. Tomozawa, and M. Yamashita Efficacy of a single intravenous administration of laninamivir (an active metabolite of laninamivir octanoate) in an influenza virus infection mouse model Antivir. Res. 2013
11. W.M. Kati, A.S. Saldivar, F. Mohamadi, H.L. Sham, W.G. Laver, and W.E. Kohlbrenner GS4071 is a slow-binding inhibitor of influenza neuraminidase from both A and B strains Biochem. Biophys. Res. Commun. 244 1998 408 413
12. J.H. Kim, R. Resende, T. Wennekes, H.M. Chen, N. Bance, S. Buchini, A.G. Watts, P. Pilling, V.A. Streltsov, M. Petric, R. Liggins, S. Barrett, J.L. McKimm-Breschkin, M. Niikura, and S.G. Withers Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity Science 340 2013 71 75
13. M. Kiso, S. Kubo, M. Ozawa, Q.M. Le, C.A. Nidom, M. Yamashita, and Y. Kawaoka Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses PLoS Pathog. 6 2010 e1000786
14. S. Kubo, T. Tomozawa, M. Kakuta, A. Tokumitsu, and M. Yamashita Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration Antimicrob. Agents Chemother. 54 2010 1256 1264
15. S.-K. Leang, S. Kwok, S.G. Sullivan, S. Maurer-Stroh, A. Kelso, I.G. Barr, and A.C. Hurt Peramivir and laninamivir susceptibility of circulating influenza A and B viruses Influenza Other Resp. Viruses 8 2014 135 139
16. J.L. McKimm-Breschkin, S. Barrett, Pudjiatmoko, M. Azhar, F.Y. Wong, P. Selleck, P.G. Mohr, J. McGrane, and M. Kim I222 neuraminidase mutations further reduce oseltamivir susceptibility of indonesian clade 2.1 highly pathogenic avian influenza A(H5N1) viruses PLoS One 8 2013 e66105
17. J.L. McKimm-Breschkin, C. Rootes, P.G. Mohr, S. Barrett, and V.A. Streltsov In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir J. Antimicrob. Chemother. 67 2012 1874 1883
18. A.J. Oakley, S. Barrett, T.S. Peat, J. Newman, V.A. Streltsov, L. Waddington, T. Saito, M. Tashiro, and J.L. McKimm-Breschkin Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses J. Med. Chem. 53 2010 6421 6431
19. M.S. Pegg, and M. von Itzstein Slow-binding inhibition of sialidase from influenza virus Biochem. Mol. Biol. Int. 32 1994 851 858
20. M. Samson, Y. Abed, F.M. Desrochers, S. Hamilton, A. Luttick, S.P. Tucker, M.J. Pryor, and G. Boivin Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir Antimicrob. Agents Chemother. 58 2014 5220 5228
21. B.J. Smith, J.L. McKimm-Breschkin, M. McDonald, R.T. Fernley, J.N. Varghese, and P.M. Colman Structural studies of the resistance of influenza virus neuramindase to inhibitors J. Med. Chem. 45 2002 2207 2212
22. M. Tashiro, J.L. McKimm-Breschkin, T. Saito, A. Klimov, C. Macken, M. Zambon, and F.G. Hayden Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007 Antivir. Ther. 14 2009 751 761
23. A.A. Thabet, S.H. Al-Bahlooli, A. Al-Kohlani, and A. Shoja'a Oseltamivir-resistant pandemic (H1N1)2009 in Yemen - case report Virol. J. 7 2010 88
24. M. Yamashita, T. Hirai, K. Kubota, and S. Kubo Unique characteristics of long-acting neuramindase inhibitor laninamivir octanoate (CS-8958) that explains its long lasting activity Influenza Other Resp. Viruses 5 Suppl. 1 2011 93 95